Valentis VLTS Reverse Merger
Urigen N.A., Inc. Completes Reverse Merger With Valentis, Inc.
Urigen N.A., Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders, has successfully completed its reverse merger into Valentis, Inc. on July 13, 2007. As a result, the Company plans to change its name to Urigen Pharmaceuticals, Inc. However, until such event unfolds, the Company will continue to trade on the Bulletin Board under the Valentis Inc. symbol (VLTS).
“We are pleased to have established Urigen as a publicly traded specialty pharmaceutical company focusing on urological disorders,” said William Garner, Urigen’s Chief Executive Officer. “Our management team continues to successfully execute our business plan and we look forward to routinely communicating our progress to our shareholders
|
Linear Mode
